Defibrotide, a Polydisperse Mixture of Single-stranded Phosphodiester Oligonucleotides with Lifesaving Activity in Severe Hepatic Veno-occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action
| Autor: | Kanyalakshmi Ayyanar, Massimo Iacobelli, Paul G. Richardson, Noah Kornblum, Cy A. Stein, Luba Benimetskaya |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Chemotherapy
Hepatic veno-occlusive disease medicine.medical_treatment Hepatic Veno-Occlusive Disease Hematopoietic stem cell transplantation Pharmacology Defibrotide Biology Prognosis medicine.disease Thrombomodulin Polydeoxyribonucleotides Treatment Outcome In vivo Fibrinolysis Antithrombotic Genetics medicine Humans Molecular Medicine Molecular Biology medicine.drug |
| Zdroj: | Oligonucleotides. 16:105-114 |
| ISSN: | 1557-8526 1545-4576 |
| Popis: | Veno-occlusive disease of the liver (VOD) remains a troubling and potentially fatal complication of high-dose chemotherapy and hematopoietic stem cell transplantation conditioning regimens. No effective therapy has been available for these patients to date, and the best supportive care measures remain woefully inadequate. Defibrotide (DF) (Gentium, S.p.A., Como, Italy), a polydisperse mixture of all the single-stranded phosphodiester oligodeoxyribonucleotides that can be obtained from the controlled depolymerization of porcine intestinal mucosal genomic DNA, seems to offer a safe and effective treatment for some patients suffering from severe VOD, a condition for which no accepted standard therapy currently exists. Early clinical studies evaluating the efficacy of DF for the treatment of severe VOD in patients undergoing hematopoietic stem cell transplantation have been very encouraging. Approximately 45% of the patients treated in multiple initial phase II clinical trials achieved a complete response at day +100, demonstrating normalization of serum bilirubin and resolution of the clinical syndrome. However, although multi-institutional, these represented single arm studies. A large, FDA-approved, pivotal, prospective, multi-institutional, global phase III trial of DF vs. historical controls (best available therapy) commenced in the first quarter of 2006 and should provide further validation of DF's efficacy. The drug seems to have few significant side effects, and almost all test subjects who have received this treatment have tolerated it well. Although the mechanism of action remains unclear, the drug exerts minimal systemic anticoagulant effects yet appears to induce numerous antithrombotic and profibrinolytic effects both in vitro and in vivo. It may function as an adenosine receptor agonist and causes increased concentrations of endogenous prostaglandins, which modulate thrombomodulin, platelets, and fibrinolysis. It also appears to block lipopolysaccharide (LPS)-induced tissue factor (TF) expression. However, despite the fact the DF is composed of oligonucleotides, its mechanism of action, which at the present time is unclear, is not related to Watson-Crick base pair-dependent downregulation of gene expression but is rather likely a result of its polyanionic nature. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|